Effects of Infliximab on Insulin Sensitivity and Beta Cell Function in Insulin Resistant Human Obesity

Obesity Clinical Trial

Official title:

A Prospective Trial of Anti-TNF-Alpha Chimeric Monoclonal Antibody (Infliximab, Remicade®) on Insulin Sensitivity, Beta Cell Function and Cardiovascular Risk Profile in Insulin Resistant Human Obesity

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00636142
• Other study ID #: 2005-000181-39
• Status: Completed
• Phase: Phase 4
• First received: March 11, 2008
• Last updated: March 13, 2008
• Start date: September 2005
• Est. completion date: September 2007

Study information

• Verified date: March 2008
• Source: Medical University of Graz
• Contact: n/a
• Is FDA regulated: No
• Health authority: Austria: Agency for Health and Food Safety
• Study type: Interventional

Clinical Trial Summary

The aim of the study is to test whether neutralizing TNF-alpha with infliximab affects insulin resistance and phenotypical manifestations of the metabolic syndrome as fasting plasma insulin, total body fat, plasma lipid profile or vascular endothelial function in obese male subjects.

Description:

Overweight and obesity are rapidly becoming one of the most pressing health problems. Obese subjects face an increased risk for cardiovascular events that is closely related to a cluster of metabolic disturbances (i.e. insulin resistance, hypertension, dyslipidemia and impaired fibrinolysis), collectively referred to as syndrome X. The actual mechanism underlying development of syndrome X has not been elucidated. Increased TNF-alpha activity has been proposed as a key factor.

The objectives of the study are to test whether neutralizing TNF-alpha with infliximab in obese subjects affects insulin resistance and phenotypical manifestations of the metabolic syndrome such as:

• fasting plasma insulin

• ivGTT derived parameters of insulin resistance and beta-cell function

• total body fat

• plasma lipid profile

• vascular endothelial dysfunction

Recruitment information / eligibility

• Status: Completed
• Enrollment: 9
• Est. completion date: September 2007
• Est. primary completion date: June 2007
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 20 Years to 50 Years

Eligibility

Inclusion Criteria:

• Men, 20-50 years

• BMI 30-35 kg/m2

• HOMA index > 2.5

• stable weight (+/- 2 kg) > 3 months

• Blood pressure>135/85 mmHg (or treated hypertension)

• Triglycerides>1.7 mmol/l or HDL-cholesterol<1.3 mmol/l

Adequate birth control measures for the duration of the study and should continue such precautions for 6 months after receiving the last infusion.

Hemoglobin >= 8.5 g/dL WBC >= 3.5 x 109/L Neutrophils >= 1.5 x 109/L Platelets >= 100 x 109/L SGOT (AST) and AP <3xULN

Chest radiograph within 3 months prior to first infusion with no evidence of malignancy, infection or fibrosis.

No history of latent or active TB prior to screening. No signs or symptoms suggestive of active TB upon medical history and/or physical examination.

No recent close contact with a person with active TB or, if there has been such contact, will be referred to a physician specializing in TB to undergo additional evaluation and, if warranted, receive appropriate treatment for latent TB prior to or simultaneously with the first administration of study agent.

Within 1 month prior to the first administration of study agent, either have a negative tuberculin skin test or have a newly identified positive tuberculin skin test during screening in which active TB has been ruled out and for which appropriate treatment for latent TB has been initiated either prior to or simultaneously with the first administration of study agent Have a chest radiograph taken within 3 months prior to the first administration of study agent with no evidence of current active TB or old inactive TB.

Exclusion Criteria:

• Overt Diabetes mellitus

• Current treatment with angiotensin II antagonists or ACE inhibitors.

• Treatment indication with statins according to the current NCEP III criteria.

• Treatment indication with low dose acetylsalicylic acid according to the current AHA guidelines or any other NSAID.

• Current smokers.

• Patients with (a history of) an autoimmune disease.

• Use of any investigational drug within 1 month prior to screening or within 5 half-lives of the investigational agent, whichever is longer.

• Treatment with any other therapeutic agent targeted at reducing TNFa within 3 months of screening.

• Previous administration of infliximab.

• History of receiving human/murine recombinant products or known allergy to murine products.

• Serious infections (such as pneumonia or pyelonephritis) in the previous 3 months. Less serious infections (such as acute upper respiratory tract infection [colds] or simple urinary tract infection) need not be considered exclusions at the discretion of the investigator.

• Documented HIV infection.

• Active hepatitis- B or antibodies against hepatitis-C

• History of latent or active granulomatous infection, including TB, histoplasmosis, or coccidioidomycosis, prior to screening.

• Have or have had a opportunistic infection within 6 months prior to screening.

• Have current signs or symptoms of severe, progressive or uncontrolled renal, hepatic, hematologic, gastrointestinal, endocrine, pulmonary, cardiac, neurologic, or cerebral disease (including demyelinating diseases such as multiple sclerosis).

• Concomitant congestive heart failure, including medically controlled asymptomatic patients.

• Presence of a transplanted organ

• Malignancy within the past 5 years.

• History of lymphoproliferative disease including lymphoma, or signs and symptoms suggestive of possible lymphoproliferative disease, such as lymphadenopathy of unusual size or location or splenomegaly.

• Known recent substance abuse (drug or alcohol).

• Have had a Bacille Calmette-Guerin (BCG) vaccination within 12 months of screening.

• Have a chest radiograph within 3 months prior to randomization that shows an abnormality suggestive of a malignancy or current active infection, including TB.

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Insulin Resistance
• Metabolic Syndrome
• Metabolic Syndrome X
• Obesity

Intervention

Biological:
• Infliximab
5 mg/kg body weight, maximal dose 500 mg; intravenous administration

Locations

Country	Name	City	State
Austria	Department of Internal Medicine, Medical University of Graz	Graz

Sponsors (1)

Lead Sponsor	Collaborator
Medical University of Graz

Country where clinical trial is conducted

Austria, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in fasting insulin levels		70 days	No
Secondary	Blood pressure; Vascular reactivity; Blood measurements + calculation of the HOMA; Iv-GTT; Body fat mass (DEXA); Safety;		70 days	Yes